Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model

Veterinary and Comparative Oncology

Volumn 5, Issue 1, 2007, Pages 14-30

  Lupu, M ^a,b   Storb, R ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Dog; Haematological malignancies; Haematopoietic cell transplantation

Indexed keywords

CANIS FAMILIARIS;

EID: 40549099294     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2006.00114.x     Document Type: Review

References (165)

1. Thomas ED, Lochte HL Jr, Lu WC and Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New England Journal of Medicine 1957; 257: 491-496.
2. Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD and Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man. Journal of Clinical Investigation 1959; 38: 1709-1716.
3. Bortin MM. A compendium of reported human bone marrow transplants. Transplantation 1970; 9: 571-587.
4. Barnes DWH and Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow: II. British Journal of Haematology 1957; 3: 241-252.
5. Trentin JJ. Mortality and skin transplantability in x-irradiated mice receiving isologous or heterologous bone marrow. Proceedings of the Society for Experimental Biology and Medicine 1956; 92: 688-693.
6. Jacobson LO, Marks EK, Robson MJ, Gaston EO and Zirkle RE. Effect of spleen protection on mortality following x-irradiation. Journal of Laboratory and Clinical Medicine 1949; 34: 1538-1543.
7. Jacobson LO, Simmons EL, Marks EK and Eldredge JH. Recovery from radiation injury. Science 1951; 113: 510-511.
8. Barnes DWH and Loutit JF. What is the recovery factor in spleen [Letter]? Nucleonics 1954; 12: 68-71.
9. Main JM and Prehn RT. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. Journal of the National Cancer Institute 1955; 15: 1023-1029.
10. Ford CE, Hamerton JL, Barnes DWH and Loutit JF. Cytological identification of radiation-chimaeras. Nature 1956; 177: 452-454.
11. Nowell PC, Cole LJ, Habermeyer JG and Roan PL. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Research 1956; 16: 258-261.
12. Vos O, Davids JAG., Weyzen WWH and van Bekkum DW. Evidence for cellular hypothesis in radiation protection by bone marrow cells. Acta Physiologica et Pharmacologica Neerlandica 1956; 4: 482-486.
13. Barnes DWH, Corp MJ, Loutit JF and Neal FE. Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. British Medical Journal 1956; 2: 626-627.
14. Uphoff DE. Genetic factors influencing irradiation protection by bone marrow. I. The F1 hybrid effect. Journal of the National Cancer Institute 1957; 19: 123-125.
15. Snell GD. The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility. [Review]. Scandinavian Journal of Immunology 1992; 36: 513-526.
16. Blume KG, Forman SJ and Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation, 3rd edn. Oxford, UK, Blackwell Publishing Ltd, 2004.
17. van Bekkum DW and de Vries MJ. Radiation Chimaeras. London, Logos Press Ltd, 1967.
18. Ostrander EA and Wayne RK. The canine genome [Review]. Genome Research 2005; 15: 1706-1716.
19. Storb R, Epstein RB, Bryant J, Ragde H and Thomas ED. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation 1968; 6: 587-593.
20. Storb R, Epstein RB, LeBlond RF, Rudolph RH and Thomas ED. Transplantation of allogeneic canine bone marrow stored at -80°C in dimethyl sulfoxide. [Brief report]. Blood 1969; 33: 918-923.
21. Thomas ED, Buckner CD, Rudolph RH, Fefer A, Storb R, Neiman PE, Bryant JI, Chard RL, Clift RA, Epstein RB, Fialkow PJ, Funk DD, Giblett ER, Lerner KG, Reynolds FA and Slichter S. Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood 1971; 38: 267-287.
22. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H and Buckner CD. Bone-marrow transplantation. New England Journal of Medicine 1975; 292: 832-843, 895-902.
23. Deeg HJ and Storb R. Bone marrow transplantation in dogs. In: Handbook of Animal Models in Transplantation Research. Makowka L, Cramer DV and Podesta LG, eds., Boca Raton, Florida, CRC Press Inc, 1994: 255-285.
24. Thomas ED, LeBlond R, Graham T and Storb R. Marrow infusions in dogs given midlethal or lethal irradiation. Radiation Research 1970; 41: 113-124.
25. Bull MI, Herzig GP, Graw RG Jr, Krueger GR and Bowles CA. Canine allogeneic bone marrow transplantation. Technique and variables influencing engraftment. Transplantation 1976; 22: 150-159.
26. Kolb HJ, Rieder I, Bodenberger U, Netzel B, Schäffer E, Kolb H and Thierfelder S. Dose rate and dose fractionation studies in total body irradiation of dogs. Pathologie Biologie 1979; 27: 370-372.
27. Deeg HJ, Storb R, Weiden PL, Schumacher D, Shulman H, Graham T and Thomas ED. High-dose total-body irradiation and autologous marrow reconstitution in dogs: Dose-rate-related acute toxicity and fractionation-dependent long-term survival. Radiation Research 1981; 88: 385-391.
28. Storb R and Deeg HJ. Failure of allogeneic canine marrow grafts after total body irradiation: Allogeneic 'resistance' vs transfusion induced sensitization. Transplantation 1986; 42: 571-580.
29. Storb R, Raff RF, Appelbaum FR, Schuening FW, Sandmaier BM, Graham TC and Thomas ED. What radiation dose for DLA-identical canine marrow grafts? Blood 1988; 72: 1300-1304.
30. Deeg HJ, Storb R, Longton G, Graham TC, Shulman HM, Appelbaum F and Thomas ED. Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: Effects of exposure rate, fraction size and fractionation interval on acute and delayed toxicity. International Journal of Radiation Oncology, Biology, Physics 1988; 15: 647-653.
31. Storb R, Raff RF, Appelbaum FR, Graham TC, Schuening FG, Sale G and Pepe M. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 1989; 74: 1139-1143.
32. Storb R, Epstein RB, Rudolph RH and Thomas ED. Allogeneic canine bone marrow transplantation following cyclophosphamide. Transplantation 1969; 7: 378-386.
33. Epstein RB, Storb R, Clift RA and Thomas ED. Autologous bone marrow grafts in dogs treated with lethal doses of cyclophosphamide. Cancer Research 1969; 29: 1072-1075.
34. Kolb HJ, Storb R, Weiden PL, Ochs HD, Kolb H, Graham TC, Floersheim GL and Thomas ED. Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran. Biomedicine 1974; 20: 341-351.
35. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N and Thomas ED. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation 1977; 24: 349-357.
36. Appelbaum FR, Brown P, Sandmaier B, Badger C, Schuening F, Graham TC and Storb R. Antibody-radionuclide conjugates as part of a myeloblative preparative regimen for marrow transplantation. Blood 1989; 73: 2202-2208.
37. Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR and Sandmaier BM. Selective T-cell ablation with bismuth-213-labeled anti-TCR as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003; 101: 5068-5075.
38. Sullivan RD, Stecher G and Sternberg SS. Value of bone marrow and spleen cell suspensions for survival of lethally irradiated dogs. Journal of the National Cancer Institute 1959; 23: 367-383.
39. Appelbaum FR, Herzig GP, Graw RG, Bull MI, Bowles C, Gorin NC and Deisseroth AB. Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model. Transplantation 1978; 26: 245-248.
40. Appelbaum FR. Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions. Experimental Hematology 1979; 7(Suppl. 5): 7-11.
41. Bodenberger U, Kolb HJ, Rieder I, Netzel B, Schäffer E, Kolb H and Thierfelder S. Fractionated total body irradiation and autologous bone marrow transplantation in dogs: Hemopoietic recovery after various marrow cell doses. Experimental Hematology 1980; 8: 384-394.
42. Abrams RA, McCormack K, Bowles C and Deisseroth AB. Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs. Journal of Clinical Investigation 1981; 67: 1392-1399.
43. de Revel T, Appelbaum FR, Storb R, Schuening F, Nash R, Deeg J, McNiece I, Andrews R and Graham T. Effects of granulocyte colony stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994; 83: 3795-3799.
44. Nash RA, Schuening FG, Seidel K, Appelbaum FR, Boone T, Deeg HJ, Graham TC, Hackman R, Sullivan-Pepe M and Storb R. Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood 1994; 83: 1963-1970.
45. Sandmaier BM, Storb R, Santos EB, Krizanac-Bengez L, Lian T, McSweeney PA, Yu C, Schuening FG, Deeg HJ and Graham T. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 1996; 87: 3508-3513.
46. Yunusov MY, Georges GE, Storb R, Moore P, Hagglund H, Affolter V, Lesnikova M, Gass MJ, Little M.-T., Loken M, McKenna H, Storer B and Nash RA. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease. Transplantation 2003; 75: 933-940.
47. Burroughs L, Mielcarek M, Little M.-T., Bridger G, MacFarland R, Fricker S, LaBrecque J, Sandmaier BM and Storb R. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral blood mononuclear cells in a canine transplantation model. Blood 2005; 106: 4002-4008.
48. Cavins JA, Kasakura S, Thomas ED and Ferrebee JW. Recovery of lethally irradiated dogs following infusion of autologous marrow stored at low temperature in dimethyl-sulphoxide. Blood 1962; 20: 730-734.
49. Cavins JA, Scheer SC, Thomas ED and Ferrebee JW. The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80 °C. Blood 1964; 23: 38-43.
50. Körbling M, Fliedner TM, Calvo W, Ross WM, Nothdurft W and Steinbach I. Albumin density gradient purification of canine hemopoietic blood stem cells (HBSC): Long-term allogeneic engraftment without GVH-reaction. Experimental Hematology 1979; 7: 277-288.
51. Gerhartz HH, Nothdurft W, Carbonell F and Fliedner TM. Allogeneic transplantation of blood stem cells concentrated by density gradients. Experimental Hematology 1985; 13: 136-142.
52. Storb R and Thomas ED. Graft-versus-host disease in dog and man: The Seattle experience [Review]. Immunological Reviews 1985; 88: 215-238.
53. Storb R, Kolb HJ, Deeg HJ, Weiden PL, Appelbaum F, Graham TC and Thomas ED. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplantation 1986; 1: 167-177.
54. Storb R, Deeg HJ, Raff R, Schuening F, Yu C, Sandmaier BM and Graham T. Prevention of graft-versus-host disease: Studies in a canine model [Review]. Annals of the New York Academy of Sciences 1995; 770: 149-164.
55. Epstein RB, Graham TC, Storb R and Thomas ED. Studies of marrow transplantation, chemotherapy and cross-circulation in canine lymphosarcoma. Blood 1971; 37: 349-359.
56. Weiden PL, Storb R, Sale GE, Graham TC and Thomas ED. Allogeneic hematopoietic grafts after total-body irradiation in dogs with spontaneous tumors. Journal of the National Cancer Institute 1978; 61: 353-357.
57. Appelbaum FR, Deeg HJ, Storb R, Self S, Graham TC, Sale GE and Weiden PL. Marrow transplant studies in dogs with malignant lymphoma. Transplantation 1985; 39: 499-504.
58. Thomas ED, Collins JA, Herman EC Jr and Ferrebee JW. Marrow transplants in lethally irradiated dogs given methotrexate. Blood 1962; 19: 217-228.
59. Epstein RB, Storb R, Ragde H and Thomas ED. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation 1968; 6: 45-58.
60. Rudolph RH, Hered B, Epstein RB and Thomas ED. Canine mixed leukocyte reactivity and transplantation antigens. Transplantation 1969; 8: 141-146.
61. Storb R, Rudolph RH and Thomas ED. Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. Journal of Clinical Investigation 1971; 50: 1272-1275.
62. Burnett RC, Francisco LV, DeRose SA, Storb R and Ostrander EA. Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC class I region. Mammalian Genome 1995; 6: 684-685.
63. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R and Ostrander EA. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996; 62: 876-877.
64. Francisco LV, Langston AA, Mellersh CS, Neal CL and Ostrander EA. A class of highly polymorphic tetranucleotide repeats for canine genetic mapping. Mammalian Genome 1996; 7: 359-362.
65. Wagner JL, Works JD and Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing [Brief Communication]. Tissue Antigens 1998; 52: 397-401.
66. Graumann MB, DeRose SA, Ostrander EA and Storb R. Polymorphism analysis of four canine MHC class I genes. Tissue Antigens 1998; 51: 374-381.
67. Wagner JL, Burnett RC, Works JD and Storb R. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens 1996; 48: 554-561.
68. Wagner JL, Sarmiento UM and Storb R. Cellular, serological, and molecular polymorphism of the class I and class II loci of the canine major histocompatibility complex. Tissue Antigens 2002; 59: 205-210.
69. Debelak-Fehir KM, Catchatourian R and Epstein RB. Hemopoietic colony forming units in fresh and cryopreserved peripheral blood cells of canines and man. Experimental Hematology 1975; 3: 109-116.
70. Storb R, Epstein RB and Thomas ED. Marrow repopulating ability of peripheral blood cells compared to thoracic duct cells. Blood 1968; 32: 662-667.
71. Epstein RB, Graham TC, Buckner CD, Bryant J and Thomas ED. Allogeneic marrow engraftment by cross circulation in lethally irradiated dogs. Blood 1966; 28: 692-707.
72. Storb R, Epstein RB, Ragde H and Thomas ED. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 1967; 30: 805-811.
73. Buckner D, Eisel R and Perry S. Blood cell separation in the dog by continuous flow centrifugation. Blood 1968; 31: 653-672.
74. Epstein RB, Clift RA and Thomas ED. The effect of leukocyte transfusions on experimental bacteremia in the dog. Blood 1969; 34: 782-790.
75. Herbst EW, Fliedner TM, Calvo W, Schnappauf H and Meyer H. Collection of hematopoietic stem cells from canine peripheral blood and their ability to regenerate hematopoiesis [German]. Blut 1975; 30: 265-276.
76. Zander AR, Gray KN, Ben-Ze'ev A, Johnston DA, Spitzer G, Raulston GL, McCredie KB, Jardine JH, Wu J, Gleiser C, Cardiff J and Dicke KA. Rescue by peripheral blood mononuclear cells in dogs from bone marrow failure after total-body irradiation. Transfusion 1984; 24: 42-45.
77. Ladiges WC, Storb R, Graham T and Thomas ED. Experimental techniques used to study the immune system of dogs and other large animals. In: Methods of Animal Experimentation. Gay WI and Heavener JE, eds., New York, NY, Academic Press, 1989: 103-133.
78. Lee R, Storb R, Little M-T, Joslyn A, Spector M and Kuhr CS. Percutaneous central dual-lumen catheter for apheresis in the canine. Journal of Investigative Surgery 2002; 15: 337-341.
79. Storb R, Prentice RL and Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. New England Journal of Medicine 1977; 296: 61-66.
80. Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N, Holig K, Beelen DW, Hagglund H, Basu O, Ehninger G and Fauser AA. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455-464.
81. MacDonald KP, Rowe V, Filippich C, Johnson D, Morris ES, Clouston AD, Ferrara JL and Hill GR. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: The role of donor T-cell dose and differentiation. Biology of Blood and Marrow Transplantation 2004; 10: 373-385.
82. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers MED, Lilleby K, Chauncey TR, Storb R and Appelbaum FR. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine 2001; 344: 175-181.
83. Thomas ED. High-dose therapy and bone marrow transplantation. Seminars in Oncology 1986; 12: 15-20.
84. Weiden PL, Storb R, Shulman H and Graham TC. Dimethyl myleran and autologous marrow grafting for the treatment of spontaneous canine lymphoma. European Journal of Cancer and Clinical Oncology 1977; 13: 1411-1415.
85. Weiden PL, Storb R, Lerner KG, Kao GF, Graham TC and Thomas ED. Treatment of canine malignancies by 1200 R total body irradiation and autologous marrow grafts. Experimental Hematology 1975; 3: 124-134.
86. Ferrebee JW, Lochte HL Jr, Jaretzki A, III, Sahler OD and Thomas ED. Successful marrow homograft in the dog after radiation. Surgery 1958; 43: 516-520.
87. Weiden PL, Storb R, Deeg HJ, Graham TC and Thomas ED. Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy-induced remissions. Blood 1979; 54: 1039-1049.
88. Weiden PL, Storb R, Deeg HJ and Graham TC. Total body irradiation and autologous marrow transplantation as consolidation therapy for spontaneous canine lymphoma in remission. Experimental Hematology 1979; 7(Suppl. 5): 160-163.
89. Deeg HJ, Appelbaum FR, Weiden PL, Hackman RC, Graham TC and Storb R. Autologous marrow transplantation as consolidation therapy for canine lymphoma: Efficacy and toxicity of various regimens of total body irradiation. American Journal of Veterinary Research 1985; 46: 2016-2018.
90. Mannick JA, Lochte HL Jr, Ashley CA, Thomas ED and Ferrebee JW. Autografts of bone marrow in dogs after lethal total-body radiation. Blood 1960; 15: 255-266.
91. Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG, Shulman H and Pepe M. Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. International Journal of Radiation Oncology, Biology, Physics 1993; 26: 275-283.
92. Schuening FG, Storb R, Goehle S, Graham TC, Hackman R, Mori M, Sousa LM and Appelbaum FR. Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. Blood 1990; 76: 636-640.
93. Schuening FG, von Kalle C, Kiem H.-P., Appelbaum FR, Deeg HJ, Pepe M, Gooley T, Graham TC, Hackman R and Storb R. Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. Experimental Hematology 1997; 25: 1240-1245.
94. Vriesendorp HM, Klapwijk WM, van Kessel AMC, Zurcher C and van Bekkum DW. Lasting engraftment of histoincompatible bone marrow cells in dogs. Transplantation 1981; 31: 347-352.
95. Deeg HJ, Storb R, Shulman HM, Weiden PL, Graham TC and Thomas ED. Engraftment of DLA-nonidentical unrelated canine marrow after high-dose fractionated total body irradiation. Transplantation 1982; 33: 443-446.
96. Deeg HJ, Storb R, Weiden PL, Shulman HM, Graham TC, Torok-Storb BJ and Thomas ED. Abrogation of resistance to and enhancement of DLA-nonidentical unrelated marrow grafts in lethally irradiated dogs by thoracic duct lymphocytes. Blood 1979; 53: 552-557.
97. Deeg HJ, Sale GE, Storb R, Graham TC, Schuening F, Appelbaum FR and Thomas ED. Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate. Transplantation 1987; 44: 340-345.
98. Schuening F, Storb R, Goehle S, Meyer J, Graham TC, Deeg HJ, Appelbaum FR, Sale GE, Graf L and Loughran TP Jr. Facilitation of engraftment of DLA-nonidentical marrow by treatment of recipients with monoclonal antibody directed against marrow cells surviving radiation. Transplantation 1987; 44: 607-613.
99. Sandmaier BM, Storb R, Appelbaum FR and Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood 1990; 76: 630-635.
100. Sandmaier BM, Storb R, Bennett KL, Appelbaum FR and Santos EB. Epitope specificity of CD44 for monoclonal antibody dependent facilitation of marrow engraftment in a canine model. Blood 1998; 91: 3494-3502.
101. Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR and Storb R. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100: 318-326.
102. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem H.-P., Nash RA, McSweeney PA and Wagner JL. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999; 94: 2523-2529.
103. Storb R, Epstein RB, Graham TC and Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240-246.
104. Kolb HJ, Storb R, Graham TC, Kolb H and Thomas ED. Antithymocyte serum and methotrexate for control of graft-versus-host disease in dogs. Transplantation 1973; 16: 17-23.
105. Storb R, Kolb HJ, Graham TC, Kolb H, Weiden PL and Thomas ED. Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 1973; 42: 601-609.
106. Deeg HJ, Storb R, Weiden PL, Graham T, Atkinson K and Thomas ED. Cyclosporin-A: Effect on marrow engraftment and graft-versus-host disease in dogs. Transplantation Proceedings 1981; 13: 402-409.
107. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, Graham TC and Thomas ED. Cyclosporin A and methotrexate in canine marrow transplantation: Engraftment, graft-versus-host disease, and induction of tolerance. Transplantation 1982; 34: 30-35.
108. Raff RF, Storb R, Graham T, Fidler JM, Sale GE, Johnston B, Deeg HJ, Pepe M, Schuening F, Appelbaum FR, Bauer RJ, Young JD, Marafino BJ, Ando DG and Braude IA. Pharmacologic, toxicologic and marrow transplantation studies in dogs given succinyl acetone. Transplantation 1992; 54: 813-820.
109. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, Van Der Jagt R and Schuening FG. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation 1993; 56: 800-807.
110. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H.-P., Leisenring W and Shulman H. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
111. Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E and Storb R. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
112. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, Kiem H.-P., McSweeney P, Seidel K, Georges G and Zaucha JM. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999; 94: 1131-1136.
113. Yu C, Linsley P, Seidel K, Sale G, Deeg HJ, Nash RA and Storb R. Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. Transplantation 2000; 69: 450-454.
114. Lee RS, Kuhr CS, Sale GE, Zellmer E, Hogan WJ, Storb R and Little M.-T. FTY720 does not abrogate acute graft-versus-host disease in the DLA-nonidentical unrelated canine model. Transplantation 2003; 76: 1155-1158.
115. Hogan WJ, Little M.-T., Zellmer E, Friedetzky A, Diaconescu R, Gisburne S, Lee R, Kuhr C and Storb R. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biology of Blood and Marrow Transplantation 2003; 9: 489-495.
116. Kuhr CS, Lupu M, Little M.-T., Zellmer E, Sale GE and Storb R. RDP58 does not prevent graft-versus-host disease after dog leukocyte antigen-nonidentical canine hematopoietic cell transplantation. Transplantation 2006; 81: 1460-1462.
117. Lupu M, McCune JS, Kuhr CS, Gooley T and Storb R. Pharmacokinetics of oral mycophenolate mofetil in dog: Bioavailability studies and the impact of antibiotic therapy [Letter to the Editor]. Biology of Blood and Marrow Transplantation 2006; 12: 1352-1354.
118. Kolb H, Sale GE, Lerner KG, Storb R and Thomas ED. Pathology of acute graft-versus-host disease in the dog. An autopsy study of ninety-five dogs. American Journal of Pathology 1979; 96: 581-594.
119. Yu C, Storb R, Deeg HJ, Graham TC, Schuening FG, Huss R, Seidel K and Fitzsimmons WE. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. Bone Marrow Transplantation 1996; 17: 649-653.
120. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers MED, Georges GE, Grumet FC, Kiem H.-P., Torok-Storb B, Yu C, Blume KG and Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
121. Storb R, Epstein RB, Rudolph RH and Thomas ED. The effect of prior transfusion on marrow grafts between histocompatible canine siblings. Journal of Immunology 1970; 105: 627-633.
122. Deeg HJ, Aprile J, Storb R, Graham TC, Hackman R, Appelbaum FR and Schuening F. Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients. Concise Report. Blood 1988; 71: 1138-1140.
123. Deeg HJ, Aprile J, Graham TC, Appelbaum FR and Storb R. Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs. Concise Report. Blood 1986; 67: 537-539.
124. Bean MA, Storb R, Graham T, Raff R, Sale GE, Schuening F and Appelbaum FR. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation 1991; 52: 956-960.
125. Storb R and Thomas ED, for the Seattle Marrow Transplant Team. Marrow transplantation for treatment of aplastic anaemia. In: Clinics in Haematology. Thomas ED, ed., London, W.B. Saunders Company Ltd, 1978: 597-609.
126. Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Fefer A, Goodell BW, Sale GE, Sanders JE, Singer J, Stewart P and Weiden PL. Marrow transplantation in thirty 'untransfused' patients with severe aplastic anemia. Annals of Internal Medicine 1980; 92: 30-36.
127. Storb R, Doney KC, Thomas ED, Appelbaum F, Buckner CD, Clift RA, Deeg HJ, Goodell BW, Hackman R, Hansen JA, Sanders J, Sullivan K, Weiden PL and Witherspoon RP. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236-246.
128. Ochs HD, Storb R, Thomas ED, Kolb H.-J., Graham TC, Mickelson E, Parr M and Rudolph RH. Immunologic reactivity in canine marrow graft recipients. Journal of Immunology 1974; 113: 1039-1057.
129. Deeg HJ, Prentice R, Fritz TE, Sale GE, Lombard LS, Thomas ED and Storb R. Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation. International Journal of Radiation Oncology, Biology, Physics 1983; 9: 1505-1511.
130. Hager EB, Thomas ED and Ferrebee JW. Fertility of dogs after recovery from "lethal" exposure to radiation. Radiobiologia Radiotherapia 1962; 3: 1-3.
131. Chanda SM, Sellin JH, Torres CM and Yee JP. Comparative gastrointestinal effects of mycophenolate mofetil capsules and enteric-coated tablets of sodium-mycophenolic acid in beagle dogs. Transplantation Proceedings 2002; 34: 3387-3392.
132. Ladiges WC, Storb R and Thomas ED. Canine models of bone marrow transplantation. Laboratory Animal Science 1990; 40: 11-15.
133. Weiden PL, Storb R, Kolb H.-J., Ochs HD, Graham TC, Tsoi M.-S., Schroeder M.-L. and Thomas ED. Immune reactivity in dogs with spontaneous malignancy. Journal of the National Cancer Institute 1974; 53: 1049-1056.
134. Madewell BR. Chemotherapy for canine lymphosarcoma. American Journal of Veterinary Research 1975; 36: 1525-1528.
135. Owen LN, Bostock DE, Betton GR, Onions DE, Holmes J, Yoxall A and Gorman N. The role of spontaneous canine tumours in the evaluation of the aetiology and therapy of human cancer. Journal of Small Animal Practice 1975; 16: 155-162.
136. Appelbaum FR, Deeg HJ, Storb R, Graham TC, Charrier K and Bensinger W. Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. Transplantation 1986; 42: 19-22.
137. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, Goodell BW, Hickman RO, Lerner KG, Neiman PE, Sale GE, Sanders JE, Singer J, Stevens M, Storb R and Weiden PL. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533.
138. Weiden P, Robinett B, Graham TC, Adamson JW and Storb R. Canine cyclic neutropenia. A stem cell defect. Journal of Clinical Investigation 1974; 53: 950-953.
139. Felsburg PJ, Somberg RL, Hartnett BJ, Suter SF, Henthorn PS, Moore PF, Weinberg KI and Ochs HD. Full immunologic reconstitution following nonconditioned bone marrow transplantation for canine X-linked severe combined immunodeficiency. Blood 1997; 90: 3214-3221.
140. Weiden PL, Hackman RC, Deeg HJ, Graham TC, Thomas ED and Storb R. Long-term survival and reversal of iron overload after marrow transplantation in dogs with congenital hemolytic anemia. Blood 1981; 57: 66-70.
141. Zaucha JM, Yu C, Lothrop CD Jr, Nash RA, Sale G, Georges G, Kiem H.-P., Niemeyer GP, Dufresne M, Cao Q and Storb R. Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. Biology of Blood and Marrow Transplantation 2001; 7: 14-24.
142. Takatu A, Nash RA, Zaucha JM, Little M.-T., Georges GE, Sale GE, Zellmer E, Kuhr CS, Lothrop CD Jr and Storb R. Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia. Biology of Blood and Marrow Transplantation 2003; 9: 674-682.
143. Shull RM, Breider MA and Constantopoulos GC. Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease. Pediatric Research 1988; 24: 347-352.
144. Breider MA, Shull RM and Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. American Journal of Pathology 1989; 134: 677-692.
145. Taylor RM, Farrow BR and Stewart GJ. Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs. American Journal of Medical Genetics 1992; 42: 628-632.
146. Deeg HJ, Shulman HM, Albrechtsen D, Graham TC, Storb R and Koppang N. Batten's disease: Failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model. Clinical Genetics 1990; 37: 264-270.
147. O'Brien JS, Storb R, Raff RF, Harding J, Appelbaum F, Morimoto S, Kishimoto Y, Graham T, Ahern-Rindell A and O'Brien SL. Bone marrow transplantation in canine GM1 gangliosidosis. Clinical Genetics 1990; 38: 274-280.
148. Storb R, Marchioro TL, Graham TC, Willemin M, Hougie C and Thomas ED. Canine hemophilia and hemopoietic grafting. Blood 1972; 40: 234-238.
149. Dell'Agnola C, Wang Z, Storb R, Tapscott SJ, Kuhr CS, Hauschka SD, Lee RS, Sale GE, Zellmer E, Gisburne S, Bogan J, Kornegay JN, Cooper BJ, Gooley TA and Little M.-T.. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood 2004; 104: 4311-4318.
150. Hahn KA, Bravo L, Adams WH and Frazier DL. Naturally occurring tumors in dogs as comparative models for cancer therapy research [Review]. In Vivo 1994; 8: 133-143.
151. Vail DM Lymphoma. In: Schalm's Veterinary Hematology, 5 th edn., Feldman BF, Zinkl JG and Jain NC, eds., Philadelphia, PA, Lippincott Williams & Wilkins, 2000: 601-630.
152. Vonderhaar MA and Morrison WB Lymphosarcoma. In: Cancer in Dogs and Cats: Medical and Surgical Management, 2nd edn., Morrison WB, ed., Jackson, WY, Teton NewMedia, 2002: 641-670.
153. Laing EJ, Fitzpatrick PJ, Binnington AG, Norris AM, Mosseri A, Rider WD, Valli VE and Baur A. Half-body radiotherapy in the treatment of canine lymphoma. Journal of Veterinary Internal Medicine 1989; 3: 102-108.
154. Williams LE, Johnson JL, Hauck ML, Ruslander DM, Price GS and Thrall DE. Chemotherapy followed by half-body radiation therapy for canine lymphoma. Journal of Veterinary Internal Medicine 2004; 18: 703-709.
155. Frimberger AE, Moore AS and Quesenberry PJ. Bone marrow transplantation-based experimental therapies for canine lymphoma patients. In: 1st Meeting on Genes, Dogs, and Cancer: Emerging Concepts in Molecular Diagnosis and Therapy, Keystone, CO, USA. Modiano JF, ed., 2001, Ithaca, NY, International Veterinary Information Service (www.ivis.org), 2001; Document No. P0316.0501.
156. Lupu M, Sullivan EW, Westfall TE, Little M.-T., Weigler BJ, Moore PF, Stroup PA, Zellmer E, Kuhr C and Storb R. Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. Journal of the American Veterinary Medical Association 2006; 228: 728-732.
157. Mellersh CS, Langston AA and Acland GM, Fleming MA, Ray K, Wiegand NA, Francisco LV, Gibbs M, Aguirre GD and Ostrander EA. A linkage map of the canine genome. Genomics 1997; 46: 326-336.
158. Yu C, Ostrander E, Bryant E, Burnett R and Storb R. Use of (CA) n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation 1994; 58: 701-706.
159. Thomas ED. Bone marrow transplantation - past, present and future: Nobel lecture, December 8, 1990. In: Les Prix Nobel: The Nobel Prizes 1990. Frängsmyr T, ed., Stockholm, Sweden, Nobel Foundation, 1990: 222-230.
160. Lee J.-H., Joo Y.-D., Yim D, Lee R, Ostrander EA, Loretz C, Little M.-T., Storb R and Kuhr CS. Molecular cloning and characterization of canine ICOS. Genomics 2004; 84: 730-736.
161. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF and Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
162. Fowler DH and Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma [Review]. Leukemia and Lymphoma 2000; 38: 221-234.
163. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
164. Kuhr CS, Allen MD, Junghanss C, Zaucha JM, Marsh CL, Yunusov M, Zellmer E, Little M.-T., Torok-Storb B and Storb R. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 2002; 73: 1487-1493.
165. Trobridge G, Beard BC and Kiem H.-P. Hematopoietic stem cell transduction and amplification in large animal models. Human Gene Therapy 2005; 16: 1355-1366.